Expression of glucose transporter 1 (Glut-1) in cell lines and clinical specimens from human prostate adenocarcinoma.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Anticancer Research

• Publication date

  2004-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 15517916
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA.

  2005cited by this paper
• Expression and localization of GLUT1 and GLUT12 in prostate carcinoma

  2003cited by this paper
• Overexpression of Glut‐1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma

  2003cited by this paper
• Correlation of 18-F-fluorodeoxyglucose (FDG) accumulation with glucose transporter (Glut-1) expression in esophageal squamous cell carcinoma.

  2003cited by this paper
• Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma?

  2003cited by this paper
• Prognostic value of glucose transporter 1 expression in patients with hypopharyngeal carcinoma.

  2002cited by this paper
• Coexpression of glucose transporter 1 and matrix metalloproteinase-2 in human cancers.

  2002cited by this paper
• Glucose Transporter 1 Gene Expression is Related to Thyroid Neoplasms with an Unfavorable Prognosis: An Immunohistochemical Study

  2002cited by this paper
• Clinical Significance of Glucose Transporter 1 (GLUT1) Expression in Human Breast Carcinoma

  2002cited by this paper
• Coregulation of glucose uptake and vascular endothelial growth factor (VEGF) in two small-cell lung cancer (SCLC) sublines in vivo and in vitro.

  2001cited by this paper
• Clinical Significance of Human Erythrocyte Glucose Transporter 1 Expression at the Deepest Invasive Site of Advanced Colorectal Carcinoma

  2001cited by this paper
• Expression of glucose transporter‐1 in human gastric carcinoma

  2001cited by this paper
• Suppression of facilitative glucose transporter 1 mRNA can suppress tumor growth.

  2000cited by this paper
• Correlation of Glut-1 glucose transporter expression with [18F]FDG uptake in non-small cell lung cancer

  2000cited by this paper
• Expression of facilitative glucose transporter 1 mRNA in colon cancer was not regulated by k-ras.

  2000cited by this paper
• Expression of the human erythrocyte glucose transporter in transitional cell carcinoma of the bladder.

  2000cited by this paper
• Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer

  2000cited by this paper
• Expression of facilitative glucose transport proteins during development of squamous cell carcinomas of the head and neck

  1999cited by this paper
• Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer.

  1999cited by this paper
• Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal.

  1998cited by this paper
• The importance of glucose transport activity as the rate-limiting step of 2-deoxyglucose uptake in tumor cells in vitro.

  1998cited by this paper
• Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage.

  1998cited by this paper
• Vascular density is a predictor of cancer‐specific survival in prostatic carcinoma

  1997cited by this paper
• Dual Control of glut1 Glucose Transporter Gene Expression by Hypoxia and by Inhibition of Oxidative Phosphorylation*

  1997cited by this paper
• Quantitative microvessel density: A staging and prognostic marker for human prostatic carcinoma

  1996cited by this paper
• Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose.

  1996cited by this paper
• Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers.

  1996cited by this paper
• GLUT1 expression in human breast carcinoma: correlation with known prognostic markers.

  1995cited by this paper
• Genomic sequencing.

  1993cited by this paper
• Association of glyceraldehyde-3-phosphate dehydrogenase expression with cell motility and metastatic potential of rat prostatic adenocarcinoma.

  1993cited by this paper
• Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization.

  1993cited by this paper
• Regulation of glucose transport and GLUT1 glucose transporter expression by O2 in muscle cells in culture.

  1992cited by this paper
• Hypoxia induces glucose transporter expression in endothelial cells.

  1992cited by this paper
• The applications of PET in clinical oncology.

  1991cited by this paper
• Over-expression of facilitative glucose transporter genes in human cancer.

  1990cited by this paper
• Accelerated immunohistochemical staining by microwaves

  1990cited by this paper
• RNA probes, transcribed from synthetic DNA, for in situ hybridization.

  1988cited by this paper
• Sequence and structure of a human glucose transporter.

  1985cited by this paper
• Genomic sequencing.

  1984cited by this paper
• Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter.

  1984cited by this paper
• Detection of mrnas in sea urchin embryos by in situ hybridization using asymmetric RNA probes.

  1984cited by this paper
• Correlative histochemistry of some enzymes of carbohydrate metabolism in preneoplastic and neoplastic lesions in the rat liver.

  1982cited by this paper
• Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging.

  1974cited by this paper

• Advancements in molecular imaging probes for precision diagnosis and treatment of prostate cancer

  2025cites this paper
• The impact of dexamethasone on cellular stress responses caused by mild serum deprivation in androgen-insensitive prostate cancer cells.

  2025cites this paper
• Inhibition of glycolysis and SIRT1/GLUT1 signaling ameliorates the apoptotic effect of Leptosidin in prostate cancer cells

  2024cites this paper
• Exploring a Gemcitabine-Glucose Hybrid as a Glycoconjugate Prodrug

  2024cites this paper
• Anti-prostate cancer mechanism of black ginseng during the "nine steaming and nine sun-drying" process based on HPLC analysis combined with vector space network pharmacology

  2024cites this paper
• Biological role of fructose in the male reproductive system: Potential implications for prostate cancer

  2023cites this paper
• Prostate-Specific Membrane Antigen (PSMA) Expression Predicts Need for Early Treatment in Prostate Cancer Patients Managed with Active Surveillance

  2023cites this paper
• Carbohydrate effect of novel arene Ru(II) phenanthroline-glycoconjugates on metastatic biological processes.

  2023cites this paper
• GLUT-1 may predict metastases and death in patients with locally advanced rectal cancer

  2023cites this paper
• Preferential uptake of glucose-functionalized liposomes by cancer cells

  2022cites this paper
• Disruption of mitochondrial function augments the radiosensitivity of prostate cancer cell lines.

  2022cites this paper
• ID-Checker Technology for the Highly Selective Macroscale Delivery of Anticancer Agents to the Cancer Cells

  2022cites this paper
• Glucose transporters as markers of diagnosis and prognosis in cancer diseases

  2022cites this paper
• Glucose-Functionalized Silver Nanoparticles as a Potential New Therapy Agent Targeting Hormone-Resistant Prostate Cancer cells

  2022cites this paper
• Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients.

  2021cites this paper
• Use and Impact of Positron Emission Tomography/Computed Tomography Prior to Salvage Radiation Therapy in Men with Biochemical Recurrence After Radical Prostatectomy: A Scoping Review.

  2021cites this paper
• Pyruvate Kinase M1 Suppresses Development and Progression of Prostate Adenocarcinoma

  2021cites this paper
• Pleiotropic effects of anti-diabetic drugs: A comprehensive review.

  2020cites this paper
• Impact of the 68Ga Prostate-Specific Membrane Antigen (68Ga-PSMA) PET/CT on the Management of Prostate Cancer

  2020cites this paper
• Intra-individual dynamic comparison of 18F-PSMA-11 and 68Ga-PSMA-11 in LNCaP xenograft bearing mice

  2020cites this paper
• Increased Tumoral Microenvironmental pH Improves Cytotoxic Effect of Pharmacologic Ascorbic Acid in Castration-Resistant Prostate Cancer Cells

  2020cites this paper
• Permuted 2,4-thiazolidinedione (TZD) analogs as GLUT inhibitors and their in-vitro evaluation in leukemic cells.

  2020cites this paper
• Dynamics of Cellular Plasticity in Prostate Cancer Progression

  2020cites this paper
• Cellular internalization pathways of glucose-functionalized gold nanoparticles

  2019cites this paper
• Cypate and Cypate-Glucosamine as Near-Infrared Fluorescent Probes for In Vivo Tumor Imaging

  2019cites this paper
• Cypate and cypate-glucosamine as near infrared (NIR) fluorescent probes for in vivo tumor

  2019cites this paper
• Linking Infection and Prostate Cancer Progression: Toll-like Receptor3 Stimulation Rewires Glucose Metabolism in Prostate Cells

  2019cites this paper
• Hybrid Imaging for Male Malignancies

  2019cites this paper
• LncRNA GASL1 inhibits growth and promotes expression of apoptosis-associated proteins in prostate carcinoma cells through GLUT-1

  2019cites this paper
• A Twist-Assisted Biphenyl Photosensitizer Passable Through Glucose Channel.

  2019cites this paper
• Fructose and prostate cancer: toward an integrated view of cancer cell metabolism

  2018cites this paper
• 18 F-FDG PET / CT is still a useful tool in detection of metastatic extent in patients with high risk prostate cancer

  2018cites this paper
• Molecular Imaging of Prostate Cancer: Radiopharmaceuticals for Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT)

  2018cites this paper
• Glucose-installed biodegradable polymeric micelles for cancer-targeted drug delivery system: synthesis, characterization and in vitro evaluation

  2018cites this paper
• Current Imaging Techniques for Lymph Node Staging in Prostate Cancer: A Review

  2018cites this paper
• Role of PET imaging for biochemical recurrence following primary treatment for prostate cancer

  2018cites this paper
• Uptake mechanism of metabolic-targeted gold nanoparticles.

  2018cites this paper
• Glucose-installed, SPIO-loaded PEG-b-PCL micelles as MR contrast agents to target prostate cancer cells

  2017cites this paper
• Imaging of Glycolysis with 18F-FDG PET

  2017cites this paper
• The “ins and outs” of prostate metabolism towards carcinogenesis: the case of methoxychlor

  2017cites this paper
• Physikalisch-technische Grundlagen und Tracerentwicklung in der Positronenemissionstomografie

  2017cites this paper
• Strategie odżywcze komórek nowotworowych – przegląd wybranych typów nowotworów z uwzględnieniem zmian w poziomie i wzorze ekspresji transporterów glukozy

  2017cites this paper
• Molecular Imaging of Prostate Cancer.

  2016cites this paper
• 18F-fluorodeoxyglucose PET/CT for detection of disease in patients with prostate-specific antigen relapse following radical treatment of a local-stage prostate cancer.

  2016cites this paper
• Role of Positron Emission Tomography (PET) in the Setting ofBiochemically Recurrent Prostate Cancer

  2016cites this paper
• Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY‐876

  2016cites this paper
• Glycosylation, an effective synthetic strategy to improve the bioavailability of therapeutic peptides

  2016cites this paper
• The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration

  2016cites this paper
• Identification of novel GLUT inhibitors.

  2016cites this paper
• Diagnostic Applications of Nuclear Medicine: Prostatic Cancer

  2016cites this paper
• Identification of potential mechanisms of action of 3ʹ,4ʹ,5ʹ-trimethoxyflavonol in the inhibition of prostate cancer

  2015cites this paper
• FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy

  2015cites this paper
• Review Article Imaging of prostate cancer with PET/CT using

  2015cites this paper
• Molecular Imaging of Prostate Cancer 1

  2015cites this paper
• Gleason Score at Diagnosis Predicts the Rate of Detection of 18F-Choline PET/CT Performed When Biochemical Evidence Indicates Recurrence of Prostate Cancer: Experience with 1,000 Patients

  2015cites this paper
• Androgens enhance the glycolytic metabolism and lactate export in prostate cancer cells by modulating the expression of GLUT1, GLUT3, PFK, LDH and MCT4 genes

  2015cites this paper
• Multicentre study of 18F-FDG-PET/CT prostate incidental uptake

  2015cites this paper
• Towards the elaboration of new gold-based optical theranostics.

  2015cites this paper
• Prevalence and clinical significance of incidental 18F-fluoro-2-deoxyglucose uptake in prostate

  2015cites this paper
• Clinical impact of 18 F-fluorodeoxyglucose positron emission tomography / computed tomography in the evaluation of small cell carcinoma of the prostate

  2015cites this paper
• Imaging of prostate cancer with PET/CT using (18)F-Fluorocholine.

  2015cites this paper
• Pro-oxidant Treatment of Human Prostate Carcinoma (DU145) Induces Autoschizis Cell Death: Autophagosomes Build up out of Injured Endomembranes and Mitochondria

  2014cites this paper
• Determination of Functional Activity of Sodium Glucose Transporters in Cancer

  2014cites this paper
• Incidental abnormal FDG uptake in the prostate on 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography scans.

  2014cites this paper
• Diagnostic role of fluorodeoxyglucose positron emission tomography-computed tomography in prostate cancer

  2014cites this paper
• Incidental Abnormal FDG Uptake in the Prostate on 18-fluoro- 2-Deoxyglucose Positron Emission Tomography-Computed

  2014cites this paper
• Update on positron emission tomography for imaging of prostate cancer

  2014cites this paper
• Spectrum of the prostate lesions with increased FDG uptake on 18F-FDG PET/CT

  2014cites this paper
• Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature.

  2014cites this paper
• Imaging in prostate carcinoma.

  2013cites this paper
• Clinical impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of small cell carcinoma of the prostate.

  2013cites this paper
• Functional characterization and molecular expression of large neutral amino acid transporter (LAT1) in human prostate cancer cells.

  2013cites this paper
• Molecular Imaging in Diagnostics

  2013cites this paper
• Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations

  2013cites this paper
• Cellular distribution of Glut‐1 and Glut‐5 in benign and malignant human prostate tissue

  2012cites this paper
• Recent Development and Trends in Molecular Imaging Probes for Prostate Cancer

  2012cites this paper
• Molecular imaging of prostate cancer: PET radiotracers.

  2012cites this paper
• PET/CT in prostate cancer: non-choline radiopharmaceuticals.

  2012cites this paper
• Prostate Cancer: Role of Conventional Radionuclide and Hybrid Bone Imaging

  2012cites this paper
• NON -ADVANCED PROSTATIC CANCER

  2012cites this paper
• Investigation of the Expression of Glucose Transporter Proteins in Human Cancer Cells

  2012cites this paper
• Molecular expression and functional activity of sodium dependent multivitamin transporter in human prostate cancer cells.

  2012cites this paper
• Expression of Ki-67 (MIB-1) and GLUT-1 proteins in non-advanced prostatic cancer.

  2012cites this paper
• Glucosamine-Linked Near-Infrared Fluorescent Probes for Imaging of Solid Tumor Xenografts

  2012cites this paper
• Do androgens control the uptake of 18F-FDG, 11C-choline and 11C-acetate in human prostate cancer cell lines?

  2011cites this paper
• Prostate Cancer: PET with 18F-FDG, 18F- or 11C-Acetate, and 18F- or 11C-Choline

  2011cites this paper
• The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level

  2011cites this paper
• Prostate Cancer : PET with 18 F-FDG , 18 For 11 C-Acetate , and 18 For 11 C-Choline

  2010cites this paper
• The Role of Dysregulated Glucose Metabolism in Epithelial Ovarian Cancer

  2010cites this paper
• High glucose concentrations attenuate hypoxia-inducible factor-1alpha expression and signaling in non-tumor cells.

  2010cites this paper
• Is transketolase like 1 a target for the treatment of differentiated thyroid carcinoma? A study on thyroid cancer cell lines

  2009cites this paper
• Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET

  2009cites this paper
• Enhancement of radiation and chemotherapeutic drug responses by 2-deoxy-D-glucose in animal tumors.

  2009cites this paper
• Molecular Imaging of Prostate Cancer: A Concise Synopsis

  2009cites this paper
• Simultaneous FDG PET+/Glut1+ lung and FDG PET−/Glut1− subcarinal lymph node metastases from prostate cancer

  2009cites this paper
• FDG PET in Prostate Cancer.

  2009cites this paper
• Expression of Glut-1 is a prognostic marker for oral squamous cell carcinoma patients.

  2008cites this paper
• Dietary Carbohydrate Restriction Slows Prostate Tumor Growth

  2008cites this paper
• Hypoxia in prostate cancer: a powerful shield against tumour destruction?

  2008cites this paper
• Functional properties and genomics of glucose transporters.

  2007cites this paper